All In Biotech

Drug Trial Radar · NCT07743450

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Type 2 Diabetes Mellitus (AURORA-2)

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,560 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,560

Planned (sponsor's estimate)

Start

Aug 28, 2026

Primary completion

Jul 2028

Study completion Jul 2028

Sponsor

Sponsor type
Industry
First posted
Aug 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.

Conditions

  • Obesity
  • Overweight
  • Chronic Weight Management
  • Type 2 Diabetes Mellitus

Interventions

  • ASC30 tablets A1Drug

    ASC30 tablets A1 administered orally once daily.

  • PlaceboDrug

    Matching placebo tablets administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in body weightTime frame: Baseline to Week 72

Locations

135 sites in 6 countries. Site status is shown where the registry gives one.

  • AURORA-2 Clinical Site

    Birmingham, Alabama · Not yet recruiting

  • AURORA-2 Clinical Site

    Huntsville, Alabama · Not yet recruiting

  • AURORA-2 Clinical Site

    Peoria, Arizona · Not yet recruiting

  • AURORA-2 Clinical Site

    Phoenix, Arizona · Recruiting

  • AURORA-2 Clinical Site

    Tucson, Arizona · Not yet recruiting

  • AURORA-2 Clinical Site

    Little Rock, Arkansas · Not yet recruiting

  • AURORA-2 Clinical Site

    Banning, California · Not yet recruiting

  • AURORA-2 Clinical Site

    Chula Vista, California · Not yet recruiting

  • AURORA-2 Clinical Site

    Covina, California · Not yet recruiting

  • AURORA-2 Clinical Site

    Gardena, California · Not yet recruiting

  • AURORA-2 Clinical Site

    La Mesa, California · Not yet recruiting

  • AURORA-2 Clinical Site

    Los Angeles, California · Not yet recruiting

  • AURORA-2 Clinical Site

    Sacramento, California · Not yet recruiting

  • AURORA-2 Clinical Site

    Tarzana, California · Not yet recruiting

  • AURORA-2 Clinical Site

    Tustin, California · Not yet recruiting

  • AURORA-2 Clinical Site

    Washington D.C., District of Columbia · Not yet recruiting

  • AURORA-2 Clinical Site

    Boca Raton, Florida · Not yet recruiting

  • AURORA-2 Clinical Site

    Daytona Beach, Florida · Not yet recruiting

  • AURORA-2 Clinical Site

    Jacksonville, Florida · Not yet recruiting

  • AURORA-2 Clinical Site

    Leesburg, Florida · Not yet recruiting

  • AURORA-2 Clinical Site

    Melbourne, Florida · Recruiting

  • AURORA-2 Clinical Site

    South Miami, Florida · Not yet recruiting

  • AURORA-2 Clinical Site

    Tampa, Florida · Not yet recruiting

  • AURORA-2 Clinical Site

    The Villages, Florida · Recruiting

  • AURORA-2 Clinical Site

    Winter Park, Florida · Not yet recruiting

  • AURORA-2 Clinical Site

    Canton, Georgia · Not yet recruiting

  • AURORA-2 Clinical Site

    Decatur, Georgia · Not yet recruiting

  • AURORA-2 Clinical Site

    Union City, Georgia · Not yet recruiting

  • AURORA-2 Clinical Site

    Boise, Idaho · Not yet recruiting

  • AURORA-2 Clinical Site

    Schaumburg, Illinois · Not yet recruiting

  • AURORA-2 Clinical Site

    Evansville, Indiana · Recruiting

  • AURORA-2 Clinical Site

    Indianapolis, Indiana · Not yet recruiting

  • AURORA-2 Clinical Site

    Valparaiso, Indiana · Not yet recruiting

  • AURORA-2 Clinical Site

    Kansas City, Kansas · Not yet recruiting

  • AURORA-2 Clinical Site

    Baton Rouge, Louisiana · Not yet recruiting

  • AURORA-2 Clinical Site

    Metairie, Louisiana · Not yet recruiting

  • AURORA-2 Clinical Site

    Bowie, Maryland · Not yet recruiting

  • AURORA-2 Clinical Site

    Rockville, Maryland · Not yet recruiting

  • AURORA-2 Clinical Site

    Southfield, Michigan · Not yet recruiting

  • AURORA-2 Clinical Site

    Mankato, Minnesota · Not yet recruiting

Showing 40 of 135 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.